| Literature DB >> 25252236 |
Yara Dadalti Fragoso1, Christian Cardoso Arruda2, Walter Oleschko Arruda3, Joseph Bruno Bidin Brooks1, Alfredo Damasceno4, Carlos Augusto de Albuquerque Damasceno5, Alessandro Finkelsztejn6, Juliana Finkelsztejn6, Paulo Diniz da Gama7, Maria Cristina Brandão Giacomo8, Sidney Gomes9, Marcus Vinicius Magno Goncalves10, Andre Palma da Cunha Matta11, Marilia Manprim de Morais12, Enedina Maria Lobato de Oliveira12, Yuna Ribeiro13, Henry Koiti Sato14, Carlos Bernardo Tauil13.
Abstract
Fingolimod is a new and efficient treatment for multiple sclerosis (MS). The drug administration requires special attention to the first dose, since cardiovascular adverse events can be observed during the initial six hours of fingolimod ingestion. The present study consisted of a review of cardiovascular data on 180 patients with MS receiving the first dose of fingolimod. The rate of bradycardia in these patients was higher than that observed in clinical trials with very strict inclusion criteria for patients. There were less than 10% of cases requiring special attention, but no fatal cases. All but one patient continued the treatment after this initial dose. This is the first report on real-life administration of fingolimod to Brazilian patients with MS, and one of the few studies with these characteristics in the world.Entities:
Mesh：
Substances：
Year: 2014 PMID： 25252236 DOI： 10.1590/0004-282x20140102
Source DB: PubMed Journal: Arq Neuropsiquiatr ISSN： 0004-282X Impact factor: 1.420